Clinical Trial Update: ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation. [Phase 3]

View source ↗

Summary

The ABCSG 8 Phase 3 trial for adjuvant treatment in hormone receptor–positive breast cancer with good to moderate differentiation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED